Douglas Orr

1.9k total citations · 1 hit paper
19 papers, 1.5k citations indexed

About

Douglas Orr is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Douglas Orr has authored 19 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Immunology and 4 papers in Epidemiology. Recurrent topics in Douglas Orr's work include CAR-T cell therapy research (4 papers), HER2/EGFR in Cancer Research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Douglas Orr is often cited by papers focused on CAR-T cell therapy research (4 papers), HER2/EGFR in Cancer Research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Douglas Orr collaborates with scholars based in United States, United Kingdom and Germany. Douglas Orr's co-authors include Kurt W. Tauer, John R. Yannelli, Gailen D. Marshall, William H. West, Gary B. Thurman, Robert K. Oldham, Robert M. Goldstein, Jane Dempster, Gary L. Davis and Brian D. Brown and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Douglas Orr

19 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 974 citations William H. West, Kurt W. Tauer et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas Orr United States	11	760	686	318	169	132	19	1.5k
J. P. Johnson Germany	19	686 0.9×	561 0.8×	759 2.4×	128 0.8×	131 1.0×	31	2.0k
Ulf Petrausch Switzerland	23	450 0.6×	1.1k 1.6×	289 0.9×	289 1.7×	105 0.8×	62	1.6k
Francesco De Rosa Italy	18	392 0.5×	694 1.0×	291 0.9×	168 1.0×	68 0.5×	58	1.1k
Satoshi Wada Japan	24	830 1.1×	745 1.1×	447 1.4×	226 1.3×	191 1.4×	64	1.7k
Georg Weinlich Austria	16	582 0.8×	389 0.6×	371 1.2×	95 0.6×	154 1.2×	27	1.4k
Kaı̈ss Lassoued France	25	644 0.8×	375 0.5×	575 1.8×	60 0.4×	246 1.9×	64	1.9k
Antonella Argentiero Italy	23	406 0.5×	794 1.2×	596 1.9×	326 1.9×	162 1.2×	48	1.6k
Masato Yagita Japan	17	618 0.8×	290 0.4×	243 0.8×	59 0.3×	111 0.8×	52	1.1k
Yutaka Kurebayashi Japan	16	588 0.8×	401 0.6×	356 1.1×	259 1.5×	146 1.1×	42	1.3k
Alexandr V. Bazhin Germany	22	438 0.6×	640 0.9×	543 1.7×	136 0.8×	116 0.9×	74	1.4k

Countries citing papers authored by Douglas Orr

Since Specialization

Citations

This map shows the geographic impact of Douglas Orr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Orr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Orr more than expected).

Fields of papers citing papers by Douglas Orr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Orr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Orr. The network helps show where Douglas Orr may publish in the future.

Co-authorship network of co-authors of Douglas Orr

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Orr. A scholar is included among the top collaborators of Douglas Orr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Orr. Douglas Orr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Wee, Wen, Anthony W. Tolcher, Cesar A. Perez, et al.. (2024). Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3173–TPS3173. 3 indexed citations

Call, Justin, Douglas Orr, Debra L. Richardson, et al.. (2023). Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS3157–TPS3157. 6 indexed citations

Nemunaitis, John, Minal Barve, Douglas Orr, et al.. (2014). Summary of bi-shRNA<sup>furin</sup>/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver. Oncology. 87(1). 21–29. 41 indexed citations

Davis, Gary L., Jane Dempster, Douglas Orr, et al.. (2008). Hepatocellular Carcinoma: Management of an Increasingly Common Problem. Baylor University Medical Center Proceedings. 21(3). 266–280. 169 indexed citations

Gane, Edward, Douglas Orr, Frank Weilert, et al.. (2008). 847 PHASE II STUDY OF THE MITOCHONDRIAL ANTIOXIDANT MITOQUINONE FOR HEPATITIS C. Journal of Hepatology. 48. S318–S318. 10 indexed citations

Martín, Adrián, Robert M. Goldstein, Jane Dempster, et al.. (2006). Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation – a clinical and histological examination. Clinical Transplantation. 20(6). 695–705. 34 indexed citations

Nemunaitis, John, Douglas Orr, Casey Cunningham, et al.. (2003). Phase I Study of Oral CI-994 in Combination with Gemcitabine in Treatment of Patients with Advanced Cancer. The Cancer Journal. 9(1). 58–66. 49 indexed citations

Molmenti, Ernesto P., Jeffrey Weinstein, Eric E. Elliott, et al.. (2003). Syndromic Incidence of Ovarian Carcinoma After Liver Transplantation, with Special Reference to Anteceding Breast Cancer. Digestive Diseases and Sciences. 48(1). 187–189. 11 indexed citations

Goldstein, Robert M., et al.. (2000). TREATMENT OF HEPATOMAS IN CIRRHOTIC PATIENTS WITH RADIOFREQUENCY THERMAL ABLATION.. Transplantation. 69(Supplement). S137–S137. 1 indexed citations

10.

Nemunaitis, John, Gerald M. Edelman, Douglas Orr, et al.. (1999). Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma.. PubMed. 5(5). 292–300. 32 indexed citations

11.

Jones, Stephen E., Pankaj Khandelwal, Kristi McIntyre, et al.. (1999). Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Hematopoietic Growth Factor PIXY321 After Moderate-Dose Fluorouracil, Doxorubicin, and Cyclophosphamide in Stage II and III Breast Cancer. Journal of Clinical Oncology. 17(10). 3025–3032. 6 indexed citations

12.

Dillman, Robert O., R. K. Oldham, Kurt W. Tauer, et al.. (1991). Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.. Journal of Clinical Oncology. 9(7). 1233–1240. 87 indexed citations

13.

Obiri, Nicholas I., et al.. (1990). Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro.. PubMed. 9(2). 140–8. 13 indexed citations

14.

Oldham, R. K., et al.. (1989). Individually Specified Drug Immunoconjugates in Cancer Treatment. The International Journal of Biological Markers. 4(2). 65–77. 5 indexed citations

15.

Orr, Douglas, R. K. Oldham, M. G. Lewis, et al.. (1989). Phase I trial of mitomycin C immunoconjugates cocktails in human malignancies.. PubMed. 1(4). 229–40. 5 indexed citations

16.

West, W. H., et al.. (1988). Principles of biotherapy and its application to the treatment of disseminated renal cancer. Seminars in Surgical Oncology. 4(3). 155–160. 5 indexed citations

17.

Noe, D A, et al.. (1988). Clinical Pharmacology of Oral and Iv N-Methylformamide: A Pharmacologic Basis for Lack of Clinical Antineoplastic Activity. JNCI Journal of the National Cancer Institute. 80(9). 671–678. 12 indexed citations

18.

Oldham, R. K., M. G. Lewis, Douglas Orr, et al.. (1988). Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies.. PubMed. 1(2). 103–13. 14 indexed citations

19.

West, William H., Kurt W. Tauer, John R. Yannelli, et al.. (1987). Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer. New England Journal of Medicine. 316(15). 898–905. 974 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact